Premium
Serum Interleukin‐37: a new player in Lupus Nephritis?
Author(s) -
Tawfik Marwa G.,
Nasef Samah I.,
Omar Hanan H.,
Ghaly Mona S.
Publication year - 2017
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.13122
Subject(s) - medicine , mucocutaneous zone , lupus nephritis , immunology , disease , nephritis , systemic lupus erythematosus , interleukin , cytokine
Interleukin‐37 ( IL ‐37) has been proved to be a fundamental natural suppressor of innate immunity and inflammatory responses in autoimmune diseases such as systemic lupus erythematous ( SLE ). The purpose of this study was to assess serum IL ‐37 level in SLE patients and its correlation with disease activity and clinical and laboratory manifestations of SLE patients. Patients/methods The serum level of IL ‐37 was assessed and analyzed in 100 SLE patients and 50 healthy controls by using enzyme‐linked immunosorbent assay ( ELISA ). Clinical and laboratory manifestations and disease activity using SLE Disease Activity Index ( SLEDAI ) were also assessed. Results IL ‐37 serum level was significantly higher among SLE patients than controls. It has statistically significant correlation with disease activity, renal and mucocutaneous involvement in SLE patients. Conclusion IL ‐37 level is elevated in SLE patients in comparison to healthy controls and is correlated to high disease activity, mucocutaneous and renal involvement.